London, UK -- (MARKET WIRE) -- November 14, 2006 --
For Immediate Release 14 November, 2006
SkyePharma PLC
SKYEPHARMA APPOINTS NEW FINANCE DIRECTOR
LONDON, ENGLAND, 13 November 2006 - SkyePharma PLC (LSE: SKP; Nasdaq:
SKYE) announces today that Mr. Donald Nicholson is standing down as
Finance Director with immediate effect and will be leaving the Company to
pursue a new phase in his career. Mr. Peter Grant has been appointed
Finance Director in his place.
Peter, 51, is a Chartered Accountant with a MA (Hons), Mathematics from
Oxford University. He qualified with the firm of Peat, Marwick, Mitchell
& Co. in 1979. With over 25 years of finance and management experience in
UK companies, including nine years at listed company board level, Peter
brings extensive experience as a Finance Director at Molins PLC, Worldpay
Group PLC and Eurodis Electron PLC where he worked as Group Finance
Director until January 2005. Most recently, Peter had been interim CEO
at Voice Commerce Group, a position he held until May 2006.
Donald joined SkyePharma in February 1996 and was appointed Finance
Director in March 1997.
Jerry Karabelas, Chairman of SkyePharma, said:
"On behalf of the whole Board and staff, I would like to thank Donald for
his significant contribution and commitment to the Company over the past
ten years. We wish him well for the future.
"We are very pleased to have recruited someone of Peter's calibre to fill
the key role of Finance Director. He has played a significant role in
streamlining operations, developing new business activities and financing
initiatives. He will join our new management team of Frank Condella, CEO
and Ken Cunningham, COO and will be of great assistance in moving the
Company forward through this important stage in its development."
Disclosure under section 9.6.13 of the Listing Rules:
Mr Grant resigned from the board of Eurodis Electron PLC in January 2005
for family health reasons. In March 2005 a major franchiser gave notice
of termination of its relationship with the group, and in July 2005 the
lead finance provider reduced the facilities and the company went into
administration.
There are no other disclosures under section 9.6.13 of the Listing Rules.
For further information please contact:
SkyePharma PLC UK + 44 207 491 1777
Frank Condella, Chief Executive Officer
Ken Cunningham, Chief Operating Officer
Buchanan Communications UK + 44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich
The Trout Group US + 1 617 583 1308
Seth Lewis
Notes for editors
About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. There are now eleven approved products incorporating SkyePharma's technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit
www.skyepharma.com.
Certain statements in this news release are forward-looking statements
and are made in reliance on the safe harbour provisions of the U.S.
Private Securities Litigation Act of 1995. Although SkyePharma believes
that the expectations reflected in these forward-looking statements are
reasonable, it can give no assurance that these expectations will
materialize. Because the expectations are subject to risks and
uncertainties, actual results may vary significantly from those expressed
or implied by the forward-looking statements based upon a number of
factors, which are described in SkyePharma's 20-F and other documents on
file with the SEC. Factors that could cause differences between actual
results and those implied by the forward-looking statements contained in
this news release include, without limitation, risks related to the
development of new products, risks related to obtaining and maintaining
regulatory approval for existing, new or expanded indications of existing
and new products, risks related to SkyePharma's ability to manufacture
products on a large scale or at all, risks related to SkyePharma's and
its marketing partners' ability to market products on a large scale to
maintain or expand market share in the face of changes in customer
requirements, competition and technological change, risks related to
regulatory compliance, the risk of product liability claims, risks
related to the ownership and use of intellectual property, and risks
related to SkyePharma's ability to manage growth. SkyePharma undertakes
no obligation to revise or update any such forward-looking statement to
reflect events or circumstances after the date of this release.
This information is provided by RNS
The company news service from the London Stock Exchange